Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liang Tan

Showing results (491-500 of 495) with videos related to

Pageof 50
Sort By:
You have reached the last page of results.This site can display upto 495 results.
American Journal of Respiratory and Critical Care Medicine|September 29, 2018
Distinct "Immunoallertypes" of Disease and High Frequencies of Sensitization in Non-Cystic Fibrosis BronchiectasisMicheál Mac Aogáin, Pei Yee Tiew, Albert Yick Hou Lim, et al.
Gut|February 10, 2026
SDC1<sup>+</sup> CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancersGuan-Feng Gao, Zhao-Hui Ruan, Shi-Bo Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2025
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled TrialByoung Chul Cho, Weimin Li, Alexander I Spira, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Kidney International Reports|November 24, 2025
Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman SyndromeMichiel L A J Wieërs, Lise Allard, Viola D'Ambrosio, et al.
Pageof 50

Showing results (491-500 of 495) with videos related to

Sort By:
Pageof 50
You have reached the last page of results.This site can display upto 495 results.
American Journal of Respiratory and Critical Care Medicine|September 29, 2018
Distinct "Immunoallertypes" of Disease and High Frequencies of Sensitization in Non-Cystic Fibrosis BronchiectasisMicheál Mac Aogáin, Pei Yee Tiew, Albert Yick Hou Lim, et al.
Gut|February 10, 2026
SDC1<sup>+</sup> CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancersGuan-Feng Gao, Zhao-Hui Ruan, Shi-Bo Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2025
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled TrialByoung Chul Cho, Weimin Li, Alexander I Spira, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Kidney International Reports|November 24, 2025
Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman SyndromeMichiel L A J Wieërs, Lise Allard, Viola D'Ambrosio, et al.
Pageof 50